News
CVAC
2.330
+0.87%
0.020
Curevac’s Market Forecast Risks: Miscalculations and Trial Participant Challenges Threaten Profitability
TipRanks · 17h ago
Acuitas, CureVac settle lawsuit over COVID-19 vaccine patent rights
Acuitas, CureVac settle lawsuit over COVID-19 vaccine patent rights. Biotech company Acuitas Therapeutics and Germany-based Curevac 5CV.DE claim credit for inventions related to the vaccine. Acuitsas sued Cure Vac last year, claiming its scientists should have been co-inventors of patents.
Reuters · 1d ago
Curevac Price Target Cut to $4.00/Share From $12.00 by Leerink Partners
Dow Jones · 1d ago
Curevac Cut to Market Perform From Outperform by Leerink Partners
Dow Jones · 1d ago
Leerink Partners Downgrades CureVac to Market Perform, Lowers Price Target to $4
Benzinga · 1d ago
Analysts Offer Insights on Healthcare Companies: CureVac (CVAC) and BioMarin Pharmaceutical (BMRN)
TipRanks · 1d ago
Curevac B.V.: Report of foreign issuer
Press release · 1d ago
CureVac N.V. Reports Strong 2023 Finances and Strategic Advances
TipRanks · 2d ago
CureVac Launches Study for H5N1 Influenza Vaccine
TipRanks · 2d ago
CureVac Names New Chief Business Officer
TipRanks · 2d ago
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Boston Scientific (BSX) and CureVac (CVAC)
TipRanks · 2d ago
CureVac BV reports Q4 results
CureVac BV reports Q4 results. Revenue of €22.6M (+93.2% Y/Y). Q4 pre-tax loss was €86.5 million and €260.0 million for the three and twelve months ended December 31, 2023.
Seeking Alpha · 2d ago
CureVac Has Started The Phase 1 Part Of A Combined Phase 1/2 Study Of An Investigational Influenza A (H5N1) Pre-Pandemic Vaccine Candidate Developed In Collaboration With GSK, H5N1 Is An Avian Influenza Virus
Benzinga · 2d ago
CureVac BV FQ4 2023 Earnings Preview
CureVac BV is scheduled to announce its FQ4 earnings results on Wednesday, April 24th. The company is expected to report earnings of -$0.15 per share. The consensus revenue estimate for the quarter is $31.52 million. CureVac N.V. (CVAC)
Seeking Alpha · 3d ago
Notable earnings before Wednesday's open
Major earnings expected before the bell on Wednesday include: The Boeing, Biogen, General Dynamics, AT&T and Thermo Fisher Scientific. Other notable earnings slated for release before Wednesday's open include: Boeing, GE, TMO and others. The Boeing is expected to report its first quarter earnings after the close of trading.
Seeking Alpha · 3d ago
Weekly Report: what happened at CVAC last week (0415-0419)?
Weekly Report · 4d ago
CureVac (CVAC) Gets a Buy from Leerink Partners
TipRanks · 04/18 04:29
CVAC, SBNY and CRMD are among after hour movers
Seeking Alpha · 04/17 21:01
CureVac Partners with MD Anderson on Cancer Vaccines
TipRanks · 04/16 21:27
CureVac, MD Anderson teams up for cancer vaccines
CureVac and the University of Texas MD Anderson Cancer Center announced a co-development and licensing pact to develop cancer vaccines. Both parties will work on identifying differentiated cancer antigens. CureVac will retain worldwide exclusive rights to late-stage development, commercialization of cancer vaccine candidates.
Seeking Alpha · 04/16 11:59
More
Webull provides a variety of real-time CVAC stock news. You can receive the latest news about Curevac B.V. through multiple platforms. This information may help you make smarter investment decisions.
About CVAC
CureVac AG is a clinical-stage biopharmaceutical company, The Company strives to create transformative medicines to protect and improve people’s lives. Fueled by proprietary RNA technology platform combined with two decades of science and manufacturing, The Company is dedicated to creating novel treatments that enable the body to make its own prophylactic and therapeutic drugs.